Clinical trials: Sexual Dysfunction, Physiological
Ejaculatory Dysfunction, Hypogonadism
A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels
The purpose of this study is to see if testosterone solution 2% can impact symptoms of ejaculatory dysfunction in men with low testosterone.
- Trial name
- NCT01419236
- Testing
- Testosterone Solution 2%
- Where
- 7 sites in United States, Canada
- Volunteers
- 76 people
- Sponsor
- Eli Lilly and Company
Erectile Dysfunction
To Investigate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction.
To investigate the efficacy and safety of vardenafil in men with erectile dysfunction.
- Trial name
- NCT00661115
- Testing
- Levitra (Vardenafil, BAY38-9456)
- Where
- 6 sites in India
- Volunteers
- 173 people
- Sponsor
- Bayer
Erectile Dysfunction, Sexual Dysfunction, Physiological
Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED
A study to assess the efficacy of vardenafil, taken as a tablet both nightly or 'as needed' (immediately before intended sexual activity) compared to placebo, to evaluate its tolerability and if it can help in recovery of…
- Trial name
- NCT00492635
- Testing
- Levitra (Vardenafil, BAY38-9456)
- Where
- 86 sites in United States, Austria and 13 more
- Volunteers
- 628 people
- Sponsor
- Bayer
Treatment Outcome
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.
- Trial name
- NCT01364649
- Testing
- Vortioxetine, Escitalopram
- Where
- 62 sites in United States, Canada
- Volunteers
- 447 people
- Sponsor
- Takeda
Sexual Dysfunction, Physiological
PRILIGY Usage Patterns in Selected Populations
This study will use electronic health services databases to describe the usage patterns of dapoxetine hydrochloride (PRILIGY) in Germany and Italy with a focus on describing the extent and proportion of patients with…
- Trial name
- NCT01273545
- Testing
- PRILIGY (dapoxetine hydrochloride)
- Volunteers
- 3,000 people
- Sponsor
- Janssen Research & Development, LLC
Sexual Dysfunction, Physiological, Ejaculation
An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride
The purpose of the study is to collect information regarding the safety of dapoxetine hydrochloride when used in clinical practice to treat men with premature ejaculation.
- Trial name
- NCT01021670
- Testing
- Dapoxetine hydrochloride, Alternate care/non-dapoxetine hydrochloride treatment(s)
- Where
- 212 sites in Austria, Finland and 4 more
- Volunteers
- 10,027 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Sclerosis, Relapsing Remitting
Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)
This is an observational, prospective, non-interventional, non-controlled study planned to be conducted in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT01080053
- Where
- Argentina
- Volunteers
- 306 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Erectile Dysfunction, Sexual Dysfunction
Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction
The purpose of this study is to evaluate the efficacy and safety of dapoxetine compared to placebo in men with premature ejaculation and erectile dysfunction who are currently being treated with a phosphodiesterase-5 inhibitor…
- Trial name
- COUPLE (NCT01063855)
- Testing
- Dapoxetine, PDE5I (phosphodiesterase-5 inhibitor)
- Where
- 69 sites in United States, Argentina and 11 more
- Volunteers
- 495 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Erectile Dysfunction
A Study to Evaluate Intravaginal Ejaculation Time in Men With and Without Premature Ejaculation
The purpose of the study is to characterize intravaginal ejaculatory latency time (time between the start of vaginal intercourse and the start of intravaginal ejaculation) in men with and without premature ejaculation (PE) and to…
- Trial name
- NCT00210678
- Testing
- No intervention
- Volunteers
- 1,115 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sexual Dysfunction, Ejaculation
A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation
The primary purpose of the study is to assess the possible withdrawal effects after abruptly stopping daily therapy with dapoxetine compared with continuing daily therapy in men with premature ejaculation (PE).
- Trial name
- NCT00210613
- Testing
- Dapoxetine
- Volunteers
- 199 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Erectile Dysfunction
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).
- Trial name
- NCT00210704
- Testing
- Dapoxetine
- Volunteers
- 1,067 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Erectile Dysfunction
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).
- Trial name
- NCT00229073
- Testing
- dapoxetine
- Volunteers
- 1,116 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ejaculation
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.
The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).
- Trial name
- NCT00211107
- Testing
- Dapoxetine
- Volunteers
- 1,294 people
- Sponsor
- Alza Corporation, DE, USA
Ejaculation, Erectile Dysfunction
An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation
The purpose of this study is to evaluate the long-term safety of dapoxetine in men with rapid ejaculation.
- Conditions
- Ejaculation, Erectile Dysfunction, Sexual Dysfunction
- Trial name
- NCT01230762
- Testing
- dapoxetine
- Volunteers
- 1,774 people
- Sponsor
- Alza Corporation, DE, USA
Major Depressive Disorder (MDD)
Effects Of Antidepressants On Sexual Functioning In Adults
This study will evaluate the effects of two antidepression medications on sexual functioning.
- Trial name
- NCT00051272
- Testing
- Extended-release Bupropion Hydrochloride
- Where
- 24 sites in United States
- Volunteers
- 425 people
- Sponsor
- GlaxoSmithKline
Ejaculation
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).
- Trial name
- NCT00211094
- Testing
- Dapoxetine
- Volunteers
- 1,320 people
- Sponsor
- Alza Corporation, DE, USA
Sexual Dysfunction, Physiological
The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.
CP-866,087 is a non-hormonal compound, acting on the central nervous system, which has been shown in animal models to restore sexual function.
- Trial name
- NCT00482664
- Testing
- CP-866,087
- Where
- 12 sites in Australia, Denmark and 3 more
- Volunteers
- 84 people
- Sponsor
- Pfizer
Major Depressive Disorder (MDD)
Effects of Antidepressants on Sexual Functioning
The purpose of this trial is to study the effects of two depression medications on sexual functioning.
- Trial name
- NCT00051259
- Testing
- Extended-Release Bupropion Hydrochloride
- Where
- 23 sites in United States
- Volunteers
- 420 people
- Sponsor
- GlaxoSmithKline
Sexual Dysfunction, Physiological
Topical Alprostadil for Female Sexual Arousal Disorder
Approximately 300 patients with female sexual arousal disorder who meet eligibility criteria will be enrolled and randomized to receive either active drug or matching placebo.
- Trial name
- NCT00324948
- Testing
- Topical alprostadil (PGE-1)
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- VIVUS LLC